Rangwala Reshma
EVP & Chief Medical Officer
Rangwala Reshma has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: May 15, 2026.
On the most recent filing, Rangwala Reshma is listed as EVP & Chief Medical Officer at Karyopharm Therapeutics Inc. Inside the rolling window, Rangwala Reshma reported no open-market purchases and 3 open-market sales totaling $56K in KPTI. The largest disclosed transaction in the window is a sale of 5,066 KPTI shares on Mar 2, 2026, worth $48K.
Companies traded
Other insiders at KPTI
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$56K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 15, 2025 | KPTI | Sale | $3K |
Frequently asked questions
How many SEC Form 4 filings has Rangwala Reshma made?
Rangwala Reshma has filed 5 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Rangwala Reshma trade?
Rangwala Reshma has filed SEC Form 4 disclosures for 1 company, including KPTI.
When was Rangwala Reshma's most recent SEC Form 4 filing?
Rangwala Reshma's most recent SEC Form 4 filing on Tracefour is dated May 15, 2026.
What is Rangwala Reshma's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Rangwala Reshma is listed as EVP & Chief Medical Officer.
What is Rangwala Reshma's total buy and sell value in the current window?
Inside the rolling retention window, Rangwala Reshma bought $0 and sold $56K based on SEC Form 4 filings.
What was Rangwala Reshma's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 5,066 KPTI shares on 2026-03-02, worth $48K, per SEC Form 4 filings.